Search Tag: Markus Puhlmann
2022 04 Oct
Dr. Puhlmann has over 20 years of oncology drug development experience and has spearheaded the global development and approval of multiple cancer drugs Viewpoint Molecular Targeting, Inc, a radiopharmaceutical company developing precision lead-212-based Ī±-particle oncology therapeutics and complementary diagnostic imaging agentsĀ announced the...Read more